Skip to main content

Table 1 Basic information of involved studies

From: Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials

Author

Year

ClinicalTrials.gov number

Sample size

Histology

Treatment regime

Study phase

Dose (mg/kg)

Doi

2017

NCT02564900

12

breast or gastric or gastro-oesophageal carcinomas

trastuzumab deruxtecan

phase 1

5·4 or 6·4

Park

2020

NCT02564900

184

HER2-positive meta- static breast cancer

trastuzumab deruxtecan

phase 2

5.4

Shitara

2019

NCT02564900

44

HER2-positive gastric or gastro-oesophageal junction cancer

trastuzumab deruxtecan

phase 1

5·4 or 6·4

Tamura

2019

NCT02564900

115

HER2-positive breast cancer

trastuzumab deruxtecan

phase 1

5·4 or 6·4

Modi

2020

NCT02564900

54

advanced/metastatic HER2-low–expressing breast cancer

trastuzumab deruxtecan

phase 1

5·4 or 6·4

Shitara

2020

NCT03329690

175 (119) a

HER2-positive advanced gastric cancer

trastuzumab deruxtecan as compared with chemotherapy

phase 2

6·4

Tsurutani

2020

NCT02564900

59

HER2-expressing non-breast/non-gastric or HER2-mutant solid tumors

trastuzumab deruxtecan

phase 1

6·4

Siena

2021

NCT03384940

78

HER2-expressing metastatic colorectal cancer

trastuzumab deruxtecan

phase 2

4.4 or 5·4 or 6·4

Li

2022

NCT03505710

91

HER2-mutant non-small-cell lung cancer

trastuzumab deruxtecan

phase 2

6·4

Modi

2022

NCT03734029

557 (373) a

HER2-low metastatic breast cancer

trastuzumab deruxtecan as compared with chemotherapy

phase 3

5·4

Cortés

2022

NCT03529110

524 (257) a

HER2-positive metastatic breast cancer

trastuzumab deruxtecan as compared with trastuzumab emtansine

phase 3

5·4

  1. a The numbers in brackets represent the number of people in the trastuzumab deruxtecan group